Background The use of rituximab for refractory autoimmune blistering diseases is
increasing. Data related to rituximab for the treatment of mucous membrane pemphigoid …

BACKGROUND: Mucous membrane pemphigoid (MMP) is an autoimmune blistering
disease. In patients who do not respond to conventional therapy, rituximab (RTX) may be an …

Mucous membrane pemphigoid (MMP) is a heterogeneous group of rare, chronic,
subepithelial autoimmune blistering diseases (AIBDs) with predominant involvement of …

Background Mucous membrane pemphigoid (MMP) still represents a potentially life-and
sight-threatening disease. In a subset of patients with severe MMP, conventional …

We propose rituximab as a first-line therapy for pemphigus vulgaris and steroid-dependent
bullous pemphigoid with or without systemic steroids. A brief review of the literature …

Five patients were female and the mean age at the start of rituximab treatment was 57.6
years (range 39-80). The mean duration of disease before rituximab therapy was 53.4 …

BACKGROUND: Rituximab has been increasingly used in autoimmune blistering
dermatoses, mainly in pemphigus. However, only a few larger case series are available on …

Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease
requiring treatment with immunosuppressive medications; however, finding a therapy that …

Pemphigus vulgaris is an autoimmune blistering disease characterized by autoantibodies
that target desmoglein adhesion proteins. Rituximab and corticosteroids are Food and Drug …

Pemphigus vulgaris (PV) is a rare autoimmune blistering disorder that primarily affects the
skin and mucous membranes. Conventional treatments for PV, such as corticosteroids and …